Popular Articles

Cyberonics Provides Update On Depression Post-Approval Study
Cyberonics, Inc. (Nasdaq: CYBX) announced that the U.S. Food and Drug Administration ("FDA") has approved the company"s proposal to amend the protocol of its D-21 post-approval dosing study in depression patients treated with VNS Therapy(TM).
generic viagra online
'Shock And Kill' Research Gives New Hope For HIV 1 Eradication
Latent HIV genes can be "smoked out" of human cells. The so-called "shock and kill" technique, described in a preclinical study in BioMed Central"s open access journal Retrovirology, might represent a new milestone along the way to the discovery of a cure for HIV/AIDS.
News of the day
Boston Scientific Announces European Approval For Its Latitude(R) Patient Management System
Boston Scientific Corporation (NYSE: BSX) announced CE Mark for its LATITUDE® Patient Management system. The LATITUDE system remotely monitors patients with implantable cardiac devices, gathering information on both the device and a patient"s heart health status. The system can also detect clinical events between scheduled physician visits and send relevant data directly to a patient"s physician. It will be launched in Europe in a phased approach beginning this week.
Mental Health

Test For Strep Bacteria In Pregnant Women Misses More Cases Than Expected, Study Shows

A federal recommendation that all pregnant women undergo testing for Group B strep bacteria has helped increase the number of screenings but also has produced a high level of false negatives, according to a study published Thursday in the New England Journal of Medicine, the AP/Newark Star-Ledger reports. Group B strep is a common bacteria in the intestines or lower genital tract. Although it poses no harm to most adults, during delivery it can be spread to infants, who can develop blood infections, pneumonia, meningitis, mental retardation, hearing and vision loss, or death. Problems occur in fewer than one in 3,000 births, but the Centers for Disease Control and Prevention in 2002 issued a recommendation that all pregnant women be tested because of the potential for serious complications. The study is the first research to examine the screening program. The researchers examined data on Group B strep cases in 10 states, finding that 250 infants out of nearly 7,700 were born with the infection. They compared the results with a similar study that was conducted before the CDC recommendations were in place, finding that the screening rate rose from 48% to 85% of pregnant women. The study also found that infant infections from Group B strep declined by 27%.Researchers predicted there would be between 44 and 86 false negatives in full-term infants, based on data from previous studies. However, their results showed about 60% of infected infants -- 116 cases -- were born to women who had tested negative for Group B strep. Researchers noted that the timing of a Group B test might play a role because the infection can come quickly, and tests could have been performed before the bacteria appeared. CDC recommends that pregnant women be screened between 35 and 37 weeks" gestation. CDC researcher Stephanie Schrag, who co-authored the study, said, "Maybe it was a true negative test, and the mother later became colonized" with the bacteria before delivery (Stobbe, AP/Newark Star-Ledger, 6/17). Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women"s Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women"s Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company. © 2009 The Advisory Board Company. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):